China’s Huimei Healthcare raises $30M in Series C funding

The funds will be used by the company to develop its core-product, an AI-based Clinical Decision Support System (CDSS) called Dr Mayson.
By Dean Koh
05:19 am
Share

Credit: Huimei Healthcare

Originally founded in 2015 as a result of joint venture between Mayo Clinic and Hillhouse Capital, China’s Huimei Healthcare announced last week that it had closed $30M in Series C funding, led by Qiming Ventures and WuXi AppTech. The funds will be used by the company to develop its core-product, an AI-based Clinical Decision Support System (CDSS) called Dr Mayson, as well as for further product R & D. 

Huimei Healthcare is already working with over 60 hospitals in China, including Shanghai Ruijin Hospital, Jiangsu Provincial Hospital and Xuanwu Hospital of Capital Medical University, to develop its AI-based applications. These include Specific Disease Quality Control Systems, venous thromboembolism (VTE) prevention and treatment systems.

MARKET SNAPSHOT

Shanghai-based medical AI startup Synyi raised $36.3M in Series C funding, according to a MobiHealth News report in July. Last year, the company developed a new generation hospital informatics platform with AI capabilities.

Ping An Smart Healthcare (PASH), a subsidiary of the Ping An Group (Ping An) in China, also has their own CDSS named AskBob, which provides critical and up-to-date medical information to clinicians when dealing with patients at the point of care and for medical research and self-learning such as case discussions. AskBob is being trialled in Singapore with public healthcare groups SingHealth and the National University Health System, according to an article by Healthcare IT News. 

ON THE RECORD

"Healthcare is a highly specialised industry - safety and effectiveness are of paramount importance in the delivery of healthcare. However, in the actual clinical process, quality care management and patient safety often lag behind, and traditional management methods can no longer meet the highly specialised disease diagnosis and treatment processes. Through the combination of big data processing technologies, natural language processing (NLP) ability and computerised clinical logic, medical errors can be greatly reduced and care quality can be improved,” said Zhang Qi, founder and CEO of Huimei Healthcare in a statement.

Share